ABSTRACT
OBJECTIVE:To evaluate technology innovation capability of pharmaceutical industry in 30 provinces(regions and cities)and explore suitable innovation mode for each type. METHODS:The entropy method was adopted to establish comprehen-sive evaluation mode of technology innovation capability of pharmaceutical industry. The mode was used to measure comprehensive score and ranking of pharmaceutical industry in 30 provinces(regions and cities). Those 30 provinces(regions and cities)were di-vided into 3 types,including high technology innovation ability (type Ⅰ),medium technology innovation ability (type Ⅱ) and low technology innovation ability (type Ⅲ),and relevant suggestions on innovation mode were put forward. RESULTS & CON-CLUSIONS:According to the establishment of evaluation index system that included innovation resources input capability,innova-tion output capability,innovation potentiality and innovation environment,significant differences were found among these regions in technology innovation capability. For those 8 provinces (regions and cities) with high technology innovation ability,such as Shandong,Jiangsu and so on,which belongs to the type Ⅰ,local pharmaceutical enterprises should adopt the innovation mode of independent innovation dominant,cooperative innovation as a supplement;for those 9 provinces(regions and cities)with medium technology innovation ability,such as Hebei,Sichuan and so on,which belongs to the type Ⅱ,local pharmaceutical enterprises should select the mode of cooperative innovation of the combination of production,teaching and research;for those 13 provinces (regions and cities) with low technology innovation ability,such as Hainan,Ningxia,which belongs to the type Ⅲ,should the mode of giving priority to imitation innovation and cooperative innovation as a supplement.
ABSTRACT
The authors analyzed the status quo of the indicators, outcomes and uses,methodology, procedures and technologies of the variations management of clinical pathways in China the abroad. The outputs of the study point to the following assignments in such a management, such as further identification of the contents of such variations, and further clarification of variation analysis indicators.
ABSTRACT
Implementation of clinical pathways has a natural tie with payment modes of medical insurance,as various payment modes apply different impacts on clinical pathway.This article compared the strengths and weaknesses of various payment modes,and analyzed their impacts on clinical pathway.This way the authors provide references for decision makers of medical insurance policy.
ABSTRACT
Objective To find out present condition and differences in implementation of clinical pathways in hospitals of in China.Methods "Clinical pathway" was entered as a keyword to search in PubMed NCBI Chinese Science and Technology Periodical Database for related literatures in China from 1999 to 2009,analyzing the general implementations of clinical pathways in hospitals in different areas using the SPSS12.0 software.Results A total of 1051 relevant literatures were found.Through data analysis of these literature,differences of implementation of clinical pathways were found for 162 hospitals of different areas.It was found that the differences of total diseases among China's East,West and Central areas are significant statically.Diseases of implementation per hospital in the Central average 16.8,those in the East 8 types,while those for the West 4.4.Tertiary hospitals account for 70% as the main force of clinical pathway implementation,with diseases of implementation up to 13.7,while that under tertiary level down to 2.8.Conclusions Implementation of clinical pathways varies significantly among hospitals in different areas in China.In the process of implementing clinical pathway,appropriate management strategies should be developed according to actual situation in different hospitals in light of policies,hospital management and patient considerations.